F8 and hemophilia: For example, in the treatment of hemophilia the conjugation of immunogenic peptides to a non-immunogenic protein carrier, such as in the case of the recombinant FVIII–Fc fusion protein, decreases the immunogenicity of FVIII, leading to better clinical outcomes.